<DOC>
	<DOCNO>NCT01593527</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety result obtain chronic kidney disease ( CKD ) subgroup patient participate Phase III study large , independent patient population difficult treat gouty arthritis moderate severe CKD ( stage 3 - 4 ) .</brief_summary>
	<brief_title>Canakinumab Treatment Gouty Arthritis Flare ( ) Prevention New Flares Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Arthritis , Gouty</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis gouty arthritis History ≥ 3 gouty arthritis flare within previous 12 month Confirmed diagnosis/ document history chronic kidney disease ( CKD ) Stages 3or4 Onset current acute gouty arthritis flare within 3 day prior randomization Exclusion criterion : Hemodialysis CKD Stage 5 Organ transplantation Rheumatoid arthritis , evidence/suspicion infectious/septic arthritis , acute inflammatory arthritis Live vaccination within 3 month prior randomization Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Frequent flare</keyword>
	<keyword>Frequent attack</keyword>
	<keyword>gout</keyword>
	<keyword>gouty arthritis</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>renal impairment</keyword>
	<keyword>Anti-interleukin-1β monoclonal antibody</keyword>
	<keyword>anti-inflammatory therapy</keyword>
</DOC>